Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
about
Continued lamivudine for adults with lamivudine-resistant chronic hepatitis B virus infectionInterferon for people with lamivudine-resistant chronic hepatitis B virus infectionAdefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infectionKASL clinical practice guidelines: management of chronic hepatitis BDetection and analysis of resistance mutations of hepatitis B virusComparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysisBinding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies.Interleukin-1 receptor antagonist expression is inversely associated with outcomes of hepatitis B-related acute-on-chronic liver failure.Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.HIV/HBV coinfection in children and antiviral therapy.A case report of de novo hepatocellular carcinoma after living donor liver transplantationAntiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.LHBs can elevate the expression of MDR1 through HIF-1α in patients with CHB infection: a comparative proteomic study.Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis BMeasures to reduce mother-to-child transmission of Hepatitis B virus in China: a meta-analysis.Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug-Drug InteractionsTenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance.Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B.Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir.Modeling and Control of a Delayed Hepatitis B Virus Model with Incubation Period and Combination Treatment.Stereocontrolled Synthesis of Amino-Substituted Carbocycles by Pd-Catalyzed Alkene Carboamination Reactions.Enantioselective and Regiodivergent Addition of Purines to Terminal Allenes: Synthesis of Abacavir.Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
P2860
Q24185958-EF4B7376-DE25-48B8-A612-44D4117E440BQ24185973-354AE2DD-B7A4-4CC7-AB93-3966770B5B87Q24187530-EFED2E37-AB2C-474C-BA57-6C0B9F638266Q26752475-9B497805-D20B-4F3F-AA90-0F8ECAE9EBF3Q28266666-AD028253-5CC9-475F-964E-DAB48BBB82D0Q28539472-389C1FEF-F9E9-4069-9B27-787596647DB4Q33572382-CA7206C5-0DA4-4ED9-830C-9D612F73A47EQ33744626-9B6A8F0F-78A0-4763-BDA2-92AA4598B667Q34339608-D612B73D-9FB7-4C5D-A966-B8903F8E835BQ34538293-A701B6AD-8A28-4665-8759-6CF3C16253B9Q36410410-78B2989F-A900-43F8-9A40-50AD0DB8A4C5Q36561590-4D1CC5B9-F2D3-4621-8144-F7D0B2B80032Q36775147-D475ACBC-883C-4FE2-B5AC-F636DA73DDA3Q37116722-6646A322-92F4-4843-A8FC-A5622F2B3E62Q37195548-7E2A7E14-2D14-4996-9E8C-298EF73995C2Q37706218-3CBBEFD8-E419-410B-A916-A763E852F4F5Q38132740-2487C0DB-FB24-42DF-B03E-5D9209A02211Q38160176-506838E7-998A-418F-B84A-5BE2D0D9DF2BQ38635623-A9AD67D1-3E13-45F1-B953-0A2053AB0EE5Q40829113-9AE673A1-3C73-4EE4-9CA1-E9C3EF59C9F8Q42144275-B461AFD2-A496-42A9-BE59-6978D4B3C935Q42175048-935D1365-5EC3-4C8C-A1A9-AE6FC2B1D2FCQ42271419-F8C58C11-CFE3-4759-9BDF-C061C6C81D66Q45353268-3429A13C-DF15-44F4-B630-AF07035FFDF4Q47563099-5116A0B2-08E0-40C3-8E59-9D27332C8FFFQ48124386-26B369E3-07CB-4916-815C-2EC61DC08B7EQ48359246-B9D42817-3268-4199-B26D-273F1E08B64AQ51825625-9E6BF0A5-DDAC-49BF-9A4E-603BCA7867EF
P2860
Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Lamivudine plus adefovir combi ...... atic review and meta-analysis.
@ast
Lamivudine plus adefovir combi ...... atic review and meta-analysis.
@en
type
label
Lamivudine plus adefovir combi ...... atic review and meta-analysis.
@ast
Lamivudine plus adefovir combi ...... atic review and meta-analysis.
@en
prefLabel
Lamivudine plus adefovir combi ...... atic review and meta-analysis.
@ast
Lamivudine plus adefovir combi ...... atic review and meta-analysis.
@en
P2093
P2860
P31
P921
P356
P1433
P1476
Lamivudine plus adefovir combi ...... atic review and meta-analysis.
@en
P2093
Da-Zhi Zhang
Huai-Dong Hu
Jun-Ying Liu
Shi-Wen Tong
Yun-Jian Sheng
P2860
P2888
P356
10.1186/1743-422X-8-393
P5008
P577
2011-08-08T00:00:00Z
P6179
1005513454